Shares of CSPC Pharmaceutical Group Ltd (HKG:1093) surged over 9% on Monday after the company announced an exclusive licensing agreement with Jiangsu Alphamab Biopharmaceuticals for the development and commercialization of a novel cancer drug candidate in mainland China.
Under the agreement, CSPC PHARMA has secured the rights to develop and commercialize JSKN003, a potential best-in-class antibody-drug conjugate targeting HER2-positive solid tumors. JSKN003 has shown promising efficacy and safety data in early clinical trials, and the market for HER2-targeted drugs in China is expected to grow significantly in the coming years.
In addition to an upfront payment, Jiangsu Alphamab will also receive milestone payments and royalties on any future sales of JSKN003 in China. The deal is seen as a significant boost to CSPC PHARMA's oncology pipeline and could provide a lucrative revenue stream if the drug is successfully commercialized.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。